Search bioRxiv⌕ Search

Biology subjects

Imam, I. A.

Publications and source records attributed to Imam, I. A..

2 recordsLinked to original sources

DPLM: Dynamics-aware Protein Language Model via contrastive learning between sequence and molecular dynamics simulation trajectory

Protein dynamics play a critical role in protein function, yet such important information is missing in many protein language models (PLM). We introduce DPLM, a dynamics-aware protein language model that aligns sequence embeddings with molecular dynamics (MD) trajectory embeddings via contrastive learning. Using MD features encoded by a pretrained video model, DPLM learns sequence representations that correlate with residue-level flexibility and improve protein-level functional clustering compared to static sequence- and structure-based PLMs. Without task-specific training, DPLM outperforms ESM-based representations in zero-shot mutation-effect prediction on multiple deep mutational scanning datasets. When adapted with lightweight task-specific heads, DPLM further achieves top-tier performance on protein stability prediction and intrinsic disorder region identification, demon-strating that contrastive alignment with MD trajectories enables PLMs to capture biologically meaningful dynamic properties.

bioinformatics↗

Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling

Metastasis of Lung adenocarcinoma (LUAD) is a major cause of death in patients. Aryl hydrocarbon receptor (AHR) is an important transcription factor involved in the initiation and progression of lung cancer. Polo-like kinase 1 (PLK1), a serine/threonine kinase, is an oncogene that promotes the malignancy of multiple cancer types. Nonetheless, the interaction between these two factors and significance in lung cancer remains to be determined. Here, we demonstrate that PLK1 phosphorylates AHR at S489 in LUAD, which leads to epithelial-mesenchymal transition (EMT) and metastatic events. RNA-seq analyses show that type 2 deiodinase (DIO2) is responsible for EMT and enhanced metastatic potential. DIO2 converts tetraiodothyronine (T4) to triiodothyronine (T3), which then activates thyroid hormone signaling. In vitro and in vivo experiments demonstrate that treatment with T3 or T4 promotes the metastasis of LUAD, whereas depletion of DIO2 or deiodinase inhibitor disrupts this property. Taken together, our results identify the phosphorylation of AHR by PLK1 as a mechanism leading to the progression of LUAD and provide possible therapeutic interventions for this event.

cancer biology↗